GlobeNewswire·Nov 4, 2025, 5:07 PM ET

Turn Therapeutics Appoints Veteran Capital Markets Executive Andrew Scott as Vice President of Corporate Communications

Turn Therapeutics Inc. (NASDAQ: TTRX) appointed Andrew Scott as Vice President of Corporate Communications.
Scott will oversee investor relations, capital markets strategy, & corporate communications while supporting licensing & partnership initiatives.
The new role was created as Turn Therapeutics enters a growth phase following its public listing & strengthened balance sheet.
Bradley Burnam, CEO, stated Scott's experience will guide the company as it approaches Phase 2 clinical program completion & other milestones.
Scott brings over 30 years of experience in capital markets & corporate finance, previously serving as Managing Director at ThinkEquity LLC.
He previously held a Vice President of Business Development role at Fortress Biosciences, Inc., helping raise approximately $3 billion in life-sciences transactions.
Scott holds a BBA in Accounting from Pace University.
Turn Therapeutics develops therapies for dermatology, wound care, & infectious diseases, holding three FDA clearances for proprietary formulations.
The company is advancing late-stage clinical programs for eczema & onychomycosis while pursuing thermostable vaccine delivery for global health initiatives.